Skip to main content
SpringerLink
Log in

Therapie des metastasierten Melanoms mit BRAF-Inhibitoren

Treatment of metastatic melanoma with BRAF inhibitors

  • Gehört-Gelesen-Nachgefragt
  • Published:
Der Hautarzt Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

Literatur

  1. Chapman PB, Hauschild A, Robert C et al (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364:2507–2516

    Article  PubMed  CAS  Google Scholar 

  2. Davies H, Bignell GR, Cox C et al (2002) Mutations of the BRAF gene in human cancer. Nature 417:949–954

    Article  PubMed  CAS  Google Scholar 

  3. Curtin JA, Fridlyand J, Kageshita T et al (2005) Distinct sets of genetic alterations in melanoma. N Engl J Med 353:2135–2147

    Article  PubMed  CAS  Google Scholar 

  4. Landi MT, Bauer J, Pfeiffer RM et al (2006) MC1R germline variants confer risk for BRAF-mutant melanoma. Science 313:521–522

    Article  PubMed  CAS  Google Scholar 

  5. Pollock PM, Harper UL, Hansen KS et al (2003) High frequency of BRAF mutations in nevi. Nat Genet 33:19–20

    Article  PubMed  CAS  Google Scholar 

  6. Michaloglou C, Vredeveld LC, Soengas MS et al (2005) BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 436:720–724

    Article  PubMed  CAS  Google Scholar 

  7. Dankort D, Curley DP, Cartlidge RA et al (2009) Braf (V600E) cooperates with Pten loss to induce metastatic melanoma. Nat Genet 41:544–552

    Article  PubMed  CAS  Google Scholar 

  8. Flaherty KT, Puzanov I, Kim KB et al (2010) Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363:809–819

    Article  PubMed  CAS  Google Scholar 

  9. Hatzivassiliou G, Song K, Yen I et al (2010) RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 464:431–435

    Article  PubMed  CAS  Google Scholar 

  10. Poulikakos PI, Zhang C, Bollag G et al (2010) RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 464:427–430

    Article  PubMed  CAS  Google Scholar 

  11. Heidorn SJ, Milagre C, Whittaker S et al (2010) Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 140:209–221

    Article  PubMed  CAS  Google Scholar 

  12. Johannessen CM, Boehm JS, Kim SY et al (2010) COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 468:968–972

    Article  PubMed  CAS  Google Scholar 

  13. Nazarian R, Shi H, Wang Q et al (2010) Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468:973–977

    Article  PubMed  CAS  Google Scholar 

Download references

Interessenkonflikt

Der korrespondierende Autor weist auf folgende Beziehung hin: Der Autor erhielt von der Firma Roche und Bristol-Myers Squibb Honorare.

Author information

Authors and Affiliations

  1. Klinik und Poliklinik für Dermatologie, Universität Regensburg, Franz-Josef-Strauss-Allee 11, 93053, Regensburg, Deutschland

    C. Hafner

Authors
  1. C. Hafner
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C. Hafner.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hafner, C. Therapie des metastasierten Melanoms mit BRAF-Inhibitoren. Hautarzt 62, 696–698 (2011). https://doi.org/10.1007/s00105-011-2232-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00105-011-2232-8

Search

Navigation